Growth Metrics

Merck (MRK) Depreciation & Amortization (CF) (2016 - 2026)

Merck has reported Depreciation & Amortization (CF) over the past 18 years, most recently at $581.0 million for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 15.74% to $581.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Mar 2026, up 115.87% year-over-year, with the annual reading at $3.0 billion for FY2025, 45.0% up from the prior year.
  • Depreciation & Amortization (CF) was $581.0 million for Q1 2026 at Merck, down from $1.5 billion in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.5 billion in Q4 2025 and troughed at $1.0 million in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $448.0 million (2022), against an average of $451.2 million.
  • The largest YoY upside for Depreciation & Amortization (CF) was 579.1% in 2025 against a maximum downside of 98.82% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $430.0 million in 2022, then rose by 16.74% to $502.0 million in 2023, then grew by 3.19% to $518.0 million in 2024, then soared by 188.22% to $1.5 billion in 2025, then crashed by 61.09% to $581.0 million in 2026.
  • Per Business Quant, the three most recent readings for MRK's Depreciation & Amortization (CF) are $581.0 million (Q1 2026), $1.5 billion (Q4 2025), and $1.0 million (Q3 2025).